Strand Life Sciences Unveils StrandOmics Portal for Enhanced Rare Disease Diagnosis

Strand Life Sciences launches the StrandOmics Portal, a digital platform aiding doctors in diagnosing rare diseases with precision. The initiative includes discounted genetic testing for economically weaker patients, aiming for accessible diagnostics and better outcomes. This advancement emphasizes the company's commitment to innovative genetic solutions in India.

In a significant development on Rare Disease Day, Strand Life Sciences, a subsidiary of Reliance Industries, launched the StrandOmics Portal. This cutting-edge digital platform is crafted to streamline rare disease diagnostics, delivering rapid genetic insights to assist doctors in precise patient evaluations.

The introduction of this portal is set to revolutionize the speed and accuracy of diagnosing rare diseases, addressing the typically prolonged diagnostic challenges patients face. A key component of this initiative is the availability of reduced-cost genetic testing, targeted at patients from economically disadvantaged backgrounds, ensuring crucial diagnostic services reach a broader demographic.

"Our mission is to elevate genetic diagnostics and make them accessible to all," stated Dr. Ramesh Hariharan, CEO of Strand Life Sciences. "The StrandOmics Portal empowers healthcare professionals, offering advanced genetic insights that can enhance clinical decision-making, expedite prenatal diagnosis, and foster specialist collaboration for improved patient outcomes." Complementing its stronghold in oncology and infectious diseases, Strand Life Sciences is also expanding into consumer genomics, promising personalized genetic insights. This ongoing commitment bridges diagnostic gaps, emphasizing the firm's dedication to accessible healthcare solutions in India.

(With inputs from agencies.)